Glaucoma Competitive Landscape, 2025: Tracking 50+ Therapies Racing to Redefine Vision Care | DelveInsight

DelveInsight's "Glaucoma - Competitive Landscape, 2025" report delivers a comprehensive evaluation of the global therapeutic competition shaping the future of glaucoma management. With over 45+ companies and 50+ drugs featured, the report provides an in-depth look into current and emerging therapies across various developmental stages.

This competitive landscape analysis highlights the strategic positioning of branded and generic therapies, focusing on innovation in IOP-lowering agents, neuroprotective approaches, and fixed-dose combinations. Key product types include prostaglandin analogs, beta-blockers, rho-kinase inhibitors, and novel sustained-release drug delivery systems.

DelveInsight's report offers detailed segmentation by stage of development, route of administration (topical, implantable, injectable), and molecule type (small molecules, biologics, gene therapies). It also sheds light on inactive and discontinued products, helping identify market gaps and pivot opportunities.

Major companies such as Santen Pharmaceuticals, Nicox Ophthalmics, Qlaris Bio, VivaVision Biotech, Theratocular Biotek, and others are advancing novel assets that seek to differentiate on safety, duration of effect, or patient compliance.

In a market where chronic disease burden, aging populations, and non-adherence to therapy remain challenges, the glaucoma treatment landscape is rapidly transforming. The report dissects key trends, alliances, acquisitions, and late-stage competition expected to impact the global glaucoma therapeutics market.

Whether you are a biopharma innovator, investor, or strategist, DelveInsight's competitive intelligence provides actionable insights to stay ahead in the glaucoma drug development race.

Interested in learning more about the current treatment landscape and the key drivers shaping the glaucoma pipeline? Click here: https://www.delveinsight.com/report-store/glaucoma-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Glaucoma Competitive Landscape Report
• DelveInsight's glaucoma competitive analysis depicts a strong space with 45+ active players working to develop 50+ drugs for glaucoma treatment.
• The leading glaucoma companies include Santen Pharmaceuticals, Nicox Ophthalmics, Qlaris Bio, VivaVision Biotech, Theratocular Biotek, Perfuse Therapeutics, Omikron Italia S.r.l., Laboratoires Thea, PolyActiva Pty Ltd, Amydis Inc., and others are evaluating their lead assets to improve the glaucoma treatment landscape.
• Key glaucoma pipeline therapies in various stages of development include DE-130A, PDP-716, NCX 470, DE-126, PHP-201, Citicoline, TRS01, TC-002, T4032, Bremen, POLAT 001, BTQ-1902, Nyxol, IN-A010, VVN539, and others.
• In May 2025, OcuSciences received FDA clearance for its OcuMet Beacon, a proprietary non-invasive device for assessing retinal health.
• In May 2025, Palatin Technologies, Inc., announced new preclinical data for PL9588, a novel melanocortin receptor agonist, presented at the 2025 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. The findings support the potential of PL9588 as a topical treatment for glaucoma, combining both IOP-lowering and neuroprotective effects.
• In May 2025, Perfuse Therapeutics, Inc. announced positive 24-week results from its completed Phase I/IIa trial of PER-001, a first in class endothelin antagonist intravitreal implant for glaucoma.
• In April 2025, BVI Medical received FDA 510(k) clearance for its Leos system, a minimally invasive glaucoma device offering Laser ECP with endoscopic visualization. Leos reduces IOP by targeting aqueous humor production and is backed by emerging clinical trial data.
• In March 2025, TME Pharma and the Singapore Eye Research Institute (SERI) announced that preclinical data on mNOX-E36 will be presented at ARVO 2025. The data show mNOX-E36 is as effective as mitomycin C (MMC) in reducing post-surgical inflammation and scarring after glaucoma filtration surgery, but with a better safety profile and without damaging conjunctival blood vessels.

Request a sample and discover the recent breakthroughs happening in the glaucoma competitive landscape at https://www.delveinsight.com/report-store/glaucoma-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Glaucoma Overview
Glaucoma is a progressive eye disease characterized by damage to the optic nerve, often caused by elevated intraocular pressure (IOP). It is the leading cause of irreversible blindness worldwide. The two main types are open-angle glaucoma (OAG)-the most common form-and angle-closure (narrow-angle) glaucoma. Both refer to how fluid drains from the eye, affecting pressure levels and optic nerve health.

In OAG, the drainage angle remains open but is partially blocked, causing gradual pressure buildup and unnoticed vision loss. Angle-closure glaucoma involves a restricted or blocked drainage angle, leading to a sudden rise in eye pressure and urgent risk of vision loss.

Glaucoma often develops without early symptoms. Vision loss, especially in peripheral or central vision, may not be noticed until significant optic nerve damage has occurred. Studies now show that both central and peripheral vision can be affected earlier than previously believed.

Risk factors include family history, thin corneas, diabetes, obesity, and extreme myopia or hyperopia. Although there is no cure, early diagnosis and treatment-via eye drops, laser therapy, or surgery-can help preserve vision and slow disease progression.

Find out more about Glaucoma medication at https://www.delveinsight.com/report-store/glaucoma-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Glaucoma: Company and Product Profiles (Marketed Therapies)
1. Bausch & Lomb: Glaucoma Market Contributor
Bausch & Lomb, a subsidiary of Bausch Health, is a key player in the glaucoma market, offering a broad portfolio of eye care solutions including OTC supplements, contact lenses, surgical devices, and ophthalmic pharmaceuticals. Headquartered in New Jersey, the company has a global presence.
Product Description: VYZULTA
VYZULTA (latanoprostene bunod 0.024%) is Bausch & Lomb's leading glaucoma therapy, designed to reduce intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. As a nitric oxide-donating prostaglandin analog, it enhances aqueous humor outflow via both trabecular and uveoscleral pathways, offering superior efficacy over traditional glaucoma medications.

2. Alcon: Global Leader in Glaucoma Treatment
Alcon, the world's largest eye care device company, operates in over 60 countries and serves patients in 140+ markets. With over 75 years of innovation, Alcon remains at the forefront of glaucoma treatment through ongoing R&D investment.
Product Description: Travatan Z
TRAVATAN Z (travoprost 0.004%) is a once-daily glaucoma medication that effectively lowers IOP in open-angle glaucoma and ocular hypertension. Its IOP-lowering effect begins within 2 hours, with peak efficacy at 12 hours. It can be safely combined with other topical drugs as part of a comprehensive glaucoma therapy regimen.

Glaucoma: Company and Product Profiles (Pipeline Therapies)
1. Nicox Ophthalmics: Advancing Dual-Mechanism Glaucoma Therapy
Nicox Ophthalmics is a global company focused on developing innovative therapeutics to preserve vision and improve ocular health. It aims to establish a strong presence in both the US and European glaucoma market.
Product Description: NCX 470
NCX 470, a second-generation nitric oxide-donating prostaglandin analog, is currently in Phase III trials for open-angle glaucoma and ocular hypertension. It offers a dual mechanism of action-enhancing ocular perfusion and lowering intraocular pressure (IOP)-which may position it as a best-in-class, single-agent glaucoma medication.

2. Qlaris Bio: Targeting a Unique Glaucoma Mechanism
Qlaris Bio, a spinout of the Mayo Clinic and Nference, is developing novel ophthalmic therapies, including those targeting elevated episcleral venous pressure (EVP)-a less-addressed contributor to IOP.
Product Description: QLS-101
Their lead candidate, QLS-101, is a topical KATP channel modulator currently in Phase II trials for open-angle glaucoma and ocular hypertension. By lowering EVP and improving fluid outflow, it offers a novel approach to glaucoma treatment. Early trials show strong safety with no hyperemia and a promising efficacy signal.

Discover how emerging glaucoma therapies stack up against current treatments in the evolving market landscape: https://www.delveinsight.com/report-store/glaucoma-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Glaucoma Therapeutics Assessment
Company Analysis
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs

Scope of the Glaucoma Competitive Landscape Report
• Coverage: Global
• Key Glaucoma Companies: Santen Pharmaceuticals, Nicox Ophthalmics, Qlaris Bio, VivaVision Biotech, Theratocular Biotek, Perfuse Therapeutics, Omikron Italia S.r.l., Laboratoires Thea, PolyActiva Pty Ltd, Amydis Inc., and others.
• Key Glaucoma Pipeline Therapies: DE-130A, PDP-716, NCX 470, DE-126, PHP-201, Citicoline, TRS01, TC-002, T4032, Bremen, POLAT 001, BTQ-1902, Nyxol, IN-A010, VVN539, and others.

To dive deep into rich insights for drugs used for glaucoma treatment, visit: https://www.delveinsight.com/report-store/glaucoma-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Glaucoma Overview
4. Analytical & Commercial Assessment
5. Competitive Landscape
6. Marketed Therapies
7. Pipeline Therapies (by development stage)
8. Unmet Needs
9. Market Drivers & Barriers
10. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.